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Purpose: Estrogen exposure has been associated with the occurrence of Parkinson’s disease 
(PD), as well as many other disorders, and yet the mechanisms underlying these relations are 
often unknown. While it is likely that estrogen exposure modifies the risk of various diseases 
through many different mechanisms, some estrogen-related disease processes might work in 
similar manners and result in association between the diseases. Indeed, the association between 
diseases need not be due only to estrogen-related factors, but due to similar disease processes 
from a variety of mechanisms.
Patients and methods: All female Parkinson’s disease cases between 1982 and 2007 
(n = 12,093) were identified from the Danish National Registry of Patients, along with 
10 controls matched by years of birth and enrollment. Conditional logistic regressions (CLR) 
were used to calculate risk of PD after diagnosis of the estrogen-related diseases, endometriosis 
and   osteoporosis, conditioning on years of birth and enrollment. To identify novel associations 
between PD and any other preceding conditions, CLR was also used to calculate the odds ratios 
(ORs) for risk of PD for 202 different categories of preceding disease diagnoses. Empirical 
Bayes methods were used to identify the robust associations from the over 200 associations 
produced by this analysis.
Results: We found a positive association between osteoporosis and osteoporotic fractures and 
PD (OR = 1.18, 95% confidence interval [CI] of 1.08–1.28), while a lack of association was 
observed between endometriosis and PD (OR = 1.37, 95% CI 0.99–1.90). Using empirical Bayes 
analyses, 24 additional categories of diseases, likely unrelated to estrogen exposure, were also 
identified as potentially associated with PD.
Conclusion: We identified several novel associations, which may provide insight into common 
causal mechanisms between the diseases or greater understanding of potential early preclinical 
signs of PD. In particular, the associations with several categories of mental disorders suggest 
that these may be early warning signs of PD onset or these diseases (or the causes of these 
diseases) may predispose to PD.
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Introduction
Parkinson’s disease (PD) is a degenerative movement disorder that causes debilitating 
symptoms of tremor, rigidity, and bradykinesia usually occurring late in life. Sex is a 
consistently observed, but as of yet unexplained, risk factor for Parkinson’s disease. 
Women are two-thirds as likely as age-matched men to develop Parkinson’s disease.1 
This decreased risk of PD in women, compared with men, has led to research into 
potential neuro-protective effects of estrogen on PD risk and treatment in particular. 
Improved motor function has been associated with estrogen treatment in studies 
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of women with PD.2–4 Furthermore, studies have shown 
some, although not all, factors associated with estrogen, 
such as   hormone replacement therapy,5 length of fertile 
life,6 or receipt of hysterectomy7 are associated with PD 
risk.   However, other studies have shown no, or an inverse 
  association, to the same or similar factors.6–10
Estrogen exposure can not only be linked to Parkinson’s 
disease, but other diseases as well; both as a potential risk 
factors or protective factors. As with Parkinson’s disease, 
the underlying mechanism behind these relations is often 
unknown. Under the simplest scenarios, it could be expected 
that diseases associated with greater estrogen exposure 
would be associated with a lower risk of PD and vice 
versa. In   reality, estrogen exposure probably modifies the 
risk of various diseases through different mechanisms and 
  interactions with other susceptibility factors. Nevertheless, 
some estrogen-related disease processes may work in similar 
  manners, resulting in an association between the diseases.
Diseases related to increased  
estrogen exposure
Diseases such as breast cancer, endometrial cancer, and 
  endometriosis are associated with increased cumulative 
exposure to estrogen.11,12 We might expect to see a decreased 
incidence of PD in women suffering from these diseases, if 
the mechanisms through which estrogen modulates risk in 
any of those diseases are similar to the mechanisms in PD. 
Both breast and endometrial cancers have been examined 
as precedent conditions in case-control studies of PD, and 
no association has been found;13,14 however, many studies 
have reported overall reduced cancer rates or mortality in PD 
patients.15–20 These reports suggest a pathogenic link between 
PD and cancer that may supersede any   estrogen-related 
factors. There have not, however, been any studies of 
endometriosis,11 as a precedent condition to PD.
Diseases related to decreased  
estrogen exposure
Osteoporosis is also associated with estrogen; reduced 
  cumulative exposure to estrogen increases the risk of 
  osteoporosis.21 Osteoporosis has been studied in patients with 
PD, partially because of the increased likelihood of falls in 
PD patients that lead to fractures.22 While the   characteristic 
symptoms of postural instability in PD patients may explain 
the increased risk of fracture, lower bone   mineral density 
(BMD) has also been observed in PD patients compared with 
age and sex matched controls, particularly in   women.22,23 
  Suggested explanations for this difference include lower BMI, 
reduced exposure to sunlight, and lower vitamin D levels in 
people suffering from PD. Smoking, while related to both 
diseases, is a less likely explanation for the relationship as 
it may be associated with increased risk of osteoporosis,24,25 
as compared with an association to decreased risk of PD.26 It 
is also possible the association is due to a common estrogen 
related mechanism, increasing the risk of both diseases.
novel associations
The idea of a common mechanism behind different   disease 
  processes can extend beyond estrogen related disease 
  processes. While a number of genetic causes of PD have 
been identified these only account for a small percentage of 
cases and only very few environmental or modifiable risk 
factors of PD have been positively confirmed.27   Examining 
the entire range of preceding disease diagnoses in PD patients 
and   controls may identify certain previously unsuspected risk 
factors for PD and provide insight as to common mechanisms 
behind diseases previously considered unrelated.   Therefore, in 
this study, we will use a matched population based   case-control 
study to compare the risk of PD after   preceding diagnoses of 
the estrogen-related diseases endometriosis and osteoporosis, 
and also a wide range of disease diagnoses reported by female 
PD cases in the Danish National Registry of Patients.
Methods
Population and sample
The base population of this study is female Danish citizens 
identified in the Central Population Registry between 1982 and 
2007. All Danish citizens are assigned a unique Central Popula-
tion Registry (CPR) identification number which can be used 
to link the national registries. The Danish National Registry 
of Patients records all hospital admissions after 1977 and all 
outpatient and emergency visits after 1995. Each visit is identi-
fied with the CPR number of the patient, the date of the visit or 
hospital discharge, and a code for the primary diagnosis.28
A total of 12,247 female Parkinson’s disease cases were 
identified by searching the Danish National Registry of 
Patients for a first instance of a PD diagnostic code (ICD-8: 
342, ICD-10: G20) recorded between 1982 and 2007. Ten 
controls matched to each case by birth year, being alive 
and PD free at the time of PD diagnosis (index date) of 
the matched case, were selected using risk-set sampling 
from the Central Population Registry using their unique 
CPR number. Cases or controls were excluded when a diag-
nostic code for one of the following diseases was reported 
before the index date: Parkinsonism or secondary Parkin-
sonism (n = 159), unspecified motor neuron disease (n = 9), Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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or unspecified hereditary neuromuscular disorder (n = 5) to 
avoid misclassification. After these exclusions a final sample 
of 12,093 cases and 122,411 controls remained.
Data collection
The exposure variables relating to preceding disease diagno-
ses were also derived from the National Registry of Patients. 
For each case and control, the date and diagnostic code for 
all recorded hospital discharges or outpatient   visits between 
1977 and the index date of each subject were   collected. This 
information was then used to create the   estrogen related or 
other disease related exposure variables.
Analytic variables
First, exposure variables were created for two estrogen 
related diseases, endometriosis and osteoporosis. Subjects 
were coded as positive for endometriosis if an endometriosis 
diagnostic code (ICD-10: N80; ICD-8: 625.3) was recorded 
more than five years before their index date for the study. If 
no endometriosis diagnostic codes were recorded for a subject, 
or the codes were first recorded within five years of the index 
date, then the subject was coded as negative for   endometriosis. 
The induction period of five years was selected to allow for 
some variation around an average lag of two years observed 
between the onset of the first symptoms of PD and clinical 
diagnosis of PD.29 The same method and induction time of 
five years was used to create two   osteoporosis exposure vari-
ables. The first variable was defined strictly from diagnoses of 
osteoporosis appearing in the registry (Osteoporosis diagnos-
tic codes: ICD-10:   M80–M81; ICD-8:723). As osteoporosis 
may be s  ignificantly under-recorded in the registry of patients, 
a second   variable was created, which included the above 
osteoporosis   diagnostic codes as well as codes for hip, spine, 
and forearm fractures which are typically associated with 
osteoporosis (ICD-10: S120–S129, S220–S221, S320–S328, 
S520–S529, S720–S721; ICD-8:805, 808, 813, 820).30,31
The Danish National Registry of Patients includes diag-
nosis codes based on both ICD-8 (1977–1993) and ICD-10 
(1993-present). There are over 10,000 different diagnostic 
codes used in the registry. To create exposure variables for all 
other preceding disease diagnoses, these individual ICD codes 
were grouped into disease categories based on the ICD-8 list of 
300 causes for tabulation of hospital morbidity and the ICD-10 
tabulation list for morbidity. All ICD codes are assigned to 
a single morbidity category in each of these tabulation lists, 
allowing a morbidity category to be   identified for each ICD-8 
and ICD-10 code from the registry of patients. The morbidity 
categories of the two tabulation lists were compared, and in 
many cases, the categories remained the same from ICD-8 to 
ICD-10 allowing the categories to be directly combined. In 
other cases, multiple categories from the ICD-8 tabulation list 
needed to be combined into one category to be consistent with 
the ICD-10 tabulation list, and vice versa. Diagnostic codes and 
categories relating to external causes or injuries and routine 
hospital visits were excluded. A final list of 202 categories 
combining the ICD-10 and ICD-8 diagnostic codes was 
identified (see Appendix Table S1) and each case and control 
was defined as positive or negative for each disease category 
based on whether they had a recorded diagnostic code for that 
category more than five years before their index date.
Analytic methods
The distribution of ages and years of enrollment were 
  determined for the cases and controls. The proportion of 
cases and controls with endometriosis and osteoporosis were 
calculated, and conditional logistic regression (CLR) was used 
to calculate the odds ratios (OR) for risk of PD after diagnosis 
of endometriosis and osteoporosis   individually, conditioning 
on year of birth and year of enrollment. In addition, the CLRs 
were repeated stratifying the sample into older (.75 years) 
and younger age-at-index date (#75 years) groups. To 
  identify new associations between PD and other preceding 
conditions, CLR was similarly used to calculate the OR for 
risk of PD associated with each of the 202   morbidity catego-
ries, conditioning on year of birth and year of enrollment.
In order to identify the robust associations from the 
over 200 associations produced by this analysis, Empirical 
Table 1 Distributions of ages and year of enrollment for female 
Parkinson’s  disease  cases  identified  from  the  Danish  National 
registry of Patients between 1982 and 2007 and matched controls
All Cases 
n = 12093
Controls 
n = 122411
Age range, years
,=40  55 (,1%) 546 (,1%) 
41–50  145 (1%) 1505 (1%)
51–60 557 (5%) 5527 (5%)
61–70 1972 (16%) 20131 (16%)
71–80 5404 (45%) 54594 (45%)
81–90 3709 (31%) 37565 (31%)
90+ 251 (2%) 2543 (2%)
Date of admittance
  hospital visits
1982–1987 3533 (29%) 35349 (29%)
1988–1994 3303 (27%) 33050 (27%)
    hospital, emergency  
and outpatient visits
1995–2001 3127 (26%) 32023 (26%)
2002–2007 2130 (18%) 21989 (18%)Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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Bayes (EB) methods32 were used to shrink the effect for each 
morbidity-PD association towards the null in proportion to 
the variance of the OR. Fifty-five morbidity categories with 
fewer than five cases were excluded from the EB analysis to 
provide a baseline level of stability in the estimates. The 147 
remaining estimates were used to calculate adjusted P-values 
and ORs for each category.
Results
The distribution of ages and year of enrollment of the final 
sample of 12,093 cases and 122,411 controls is shown in Table 
1. The average age of diagnosis for the PD cases or enrollment 
for the matched controls was 75 years (standard deviation 
[SD] = 9.2). The average time from the beginning of precedent 
disease recordings in the Danish National Registry of Patients in 
1977 until enrollment in the study was 17 years (SD = 7.3).
Endometriosis shows a marginal association with 
increased risk of PD in the total sample with an OR of 
1.37 (95% confidence interval [CI] 0.99–1.90, Table 2a). 
Stratifying by age at index date suggests that this marginal 
increase is driven by a stronger positive association with PD 
in women age 75 and under, with an OR of 1.49 (95% CI of 
1.05–2.11), while in women over the age of 75 there is no 
increase in risk of PD (OR = 0.9, 95% CI of 0.36–2.24). A test 
of   homogeneity of the odds ratios, however, did not show a 
significant difference between the two groups (P = 0.31).
Diagnosis of osteoporosis appears to have no effect 
on later risk of PD, either in the entire sample or in either 
age strata, with ORs very close to the null in all cases 
(Table 2b). Table 2c shows the same results, however, 
  including   osteoporotic fractures as well as osteoporosis 
diagnoses in the definition of the exposure. This definition 
shows a much higher prevalence of osteoporosis in the 
population and shows a slight increased risk of PD in women 
with   osteoporosis with an OR of 1.18 (95% CI of 1.08–1.28). 
This risk appears to be somewhat greater in women age 75 
and under at index date, with an OR of 1.35 (95% CI of 
1.14–1.61), but also appears in women over the age of 75 
(OR = 1.13, 95% CI of 1.03–1.24).
For each of the 147 morbidity categories an effect esti-
mate (the natural log of the odds ratio, (lnOR) was obtained. 
Figure 1 shows a histogram of these 147 observed effect 
estimates and the effect estimates are normally distributed. In 
any random set of predictors, we might expect to see a normal 
distribution centered around the null with an equal number of 
positively associated predictors and negatively associated pre-
dictors. In this case, however, the distribution of effect sizes is 
not centered on the null value of zero. Many more morbidity 
categories were positively associated than were negatively 
associated, with a mean effect size across all 147 categories 
of 0.22, SD of 0.25 and a range from -0.53 to 1.15.
Empirical Bayes adjustment was used to shrink the 147 
effect estimates towards the mean estimate to identify the 
robust associations. After adjustment, 23 categories showed 
an association to PD with P , 0.05. The original and adjusted 
ORs and the adjusted P-value for these 23 categories are 
shown in Table 3, grouped together by similar pathways or 
outcomes. Consistent with the distribution seen in Figure 1, 
Table 2 numbers of female Parkinson’s disease cases and matched controls with exposure to the estrogen-related diseases, along 
with ORs and 95% confidence intervals from conditional logistic regression, conditioning on age and birth year A. Endometriosis B. 
Osteoporosis by diagnosis C. Osteoporosis by diagnosis or osteoporotic fracture
Total sample Age # 75 Age . 75
A Endometriosis no endometriosis Endometriosis no endometriosis Endometriosis no endometriosis
Cases 42 12051 37 5056 5 6995
Controls 315 122096 258 51438 57 70658
Or (95% Ci) 1.37 (0.99–1.90) 1.49 (1.05–2.11) 0.90 (0.36–2.24)
B Osteoporosis no osteoporosis Osteoporosis no osteoporosis Osteoporosis no osteoporosis
Cases 108 11985 16 5077 92 6908
Controls 1117 121294 185 51511 932 69783
Or (95% Ci) 0.99 (0.81–1.20) 0.89 (0.53–1.49) 1.00 (0.81–1.25)
C Osteoporosis 
including 
osteoporotic 
fracture
no osteoporosis 
including 
osteoporotic 
fracture
Osteoporosis 
including 
osteoporotic 
fracture
no osteoporosis 
including 
osteoporotic 
fracture
Osteoporosis 
including 
osteoporotic 
fracture
no osteoporosis 
including 
osteoporotic 
fracture
Cases 683 11410 149 4944 534 6466
Controls 6005 116406 1151 50545 4854 65861
Or (95% Ci) 1.18 (1.08–1.28) 1.35 (1.14–1.61) 1.13 (1.03–1.24)
Abbreviations: CI, confidence interval; OR, odds ratio.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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these 23 robust associations were in a casual direction, not 
protective. The association with the lowest P-value after 
adjustment was with neurotic, somatoform, and stress related 
disorders, which had an adjusted OR of 2.16 and adjusted 
P-value of 1.5E-07.
The 10 morbidity categories with the most protective 
adjusted ORs are shown in Table 4. Only three morbidity 
categories showed any protective effect after adjustment and 
none had P , 0.05. Original and EB adjusted results for all 
categories are shown in the Appendix Table S2.
Discussion
Endometriosis did not show the hypothesized protective 
association with PD, in fact the younger category of women 
demonstrated a moderately increased risk of PD associated 
with endometriosis in this study. These results suggest that 
the observed estrogen related effects in these two diseases 
likely do not work through similar mechanisms. One point 
to consider is that endometriosis is primarily diagnosed in 
young women, and is dependent on high circulating levels of 
estrogen.33 PD is primarily seen in older women and may be 
more affected by cumulative estrogen exposure rather than 
current estrogen levels,6,7 suggesting different estrogen related 
mechanisms of action. Estrogen naturally occurs in many 
forms, including 17-β estradiol, estrone, and estriol, which 
circulate at different levels as women age.34–36 In older women, 
circulating levels of estradiol, the most common estrogen 
  during the reproductive years, decrease and estrone becomes 
the most common estrogen. Therefore, it is also possible that 
the estrogen related effects of these two diseases may be 
  specifically related to different forms of the hormone.
Another factor may be the limited control for confounding 
effects of treatments or other by-products of the initial disease 
process in this study. Women suffering from endometriosis 
may be treated with oral contraceptives or in severe cases by 
hysterectomy, which have both been observed in other studies 
to be associated with increased risk of PD.7,37 Further study, 
including prescription and treatment information, would be 
warranted for these findings.
It is also of interest to note that the positive association 
appears to be only in women enrolled into the study before the 
age of 75. As endometriosis is most commonly diagnosed at a 
much younger age than PD, it is very likely that the older age 
group has increased misclassification due to the left censor-
ing of the exposure data at 1977. It is possible this apparent 
difference in the ORs is due to a bias of the observed effect 
toward the null in the older group.
On the other hand, osteoporosis (defined with   osteoporotic 
fractures) showed an increased risk of later PD diagnosis in 
both older and younger women. This result is consistent with 
the known protective effects of estrogen on both diseases. 
Notably, unlike endometriosis, both PD and osteoporosis 
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Figure 1 The distribution of effect estimates produced by conditional logistic regression for female Parkinson’s disease cases and matched controls on each of 147 morbidity 
categories derived from the Danish national registry of Patients diagnostics codes is shown. Effect estimates representing a positive association are shown in grey, while 
negative associations are shown in black.
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tend to occur later in life and may be more likely to work 
through similar processes. Osteoporosis defined strictly by 
the registry diagnoses, not including osteoporotic related 
fractures, did not show any association to later PD risk. This 
null result could be due to a number of reasons. Diagnoses 
of osteoporosis are under-reported in the Danish registry of 
patients, with incident rates approximately 8% of expected, 
and often patients whose osteoporosis is first identified by 
an osteoporotic fracture are listed only under the fracture 
codes.31 Therefore, using only osteoporosis diagnostic codes 
likely results in severe   misclassification, particularly among 
younger women. If this misclassification was   non-differential, 
Table 3 After EB adjustment, 23 out of 147 tested morbidity categories showed association to PD in the conditional logistic regression 
analysis with an adjusted P-value less than 0.05 
Grouping Morbidity category # Cases Original 
OR
EB-Adjusted 
OR
EB-Adjusted 
P-value
Psychological or  
Behavioral disorders
neurotic, stress-related and somatoform disorders 278 2.35 2.16 1.5E-07
Depression 77 2.02 1.7 0.001
Alcohol-, drug-abuse-related disease 104 1.85 1.65 0.002
Other mental and behavioral disorders 99 1.72 1.56 0.006
Mood [affective] disorders 34 2.37 1.65 0.006
neurological 
disorders
Other diseases of the nervous system 314 1.64 1.59 0.001
Mental retardation 22 3.15 1.68 0.007
Epilepsy 95 1.67 1.52 0.009
Migraine 75 1.52 1.41 0.038
Alcohol-related 
disorders
Alcohol-, drug-abuse-related disease 104 1.85 1.65 0.002
Acute pancreatitis and other diseases of the pancreas 62 1.84 1.57 0.008
Other diseases of liver and gallbladder 95 1.48 1.4 0.037
gastritis and duodenitis 171 1.39 1.36 0.042
Inflammatory 
disorders
rheumatism 327 1.56 1.52 0.004
Cystitis 307 1.52 1.48 0.006
Acute pancreatitis and other diseases of the pancreas 62 1.84 1.57 0.008
Other infectious and parasitic diseases 64 1.58 1.44 0.032
gastritis and duodenitis 171 1.39 1.36 0.042
gastro-intestinal, 
nutritional disorders
Iodine deficiency-related thyroid disorders 210 1.45 1.41 0.02
Other endocrine, nutritional and metabolic disorders 302 1.38 1.36 0.034
gastritis and duodenitis 171 1.39 1.36 0.042
Angina pectoris 326 1.48 1.45 0.01
Other diseases of the circulatory system 51 1.8 1.52 0.016
Uncategorized Diabetes mellitus 303 1.41 1.39 0.023
respiratory tuberculosis 27 2.12 1.53 0.024
Other ischemic heart diseases 396 1.37 1.36 0.031
Disorders of menstruation 802 1.32 1.32 0.045
Notes: The number of exposed cases, original Or, adjusted Or, and adjusted P-value for each category are shown. Morbidity categories are grouped with related categories, 
and can appear in more than one grouping. 
Abbreviations: PD, Parkinson’s disease; CI, confidence interval; OR, odds ratio; EB, empirical Bayes adjustment.
Table 4 The 10 disease categories with the lowest EB adjusted Ors for PD from the 147 conditional logistic regression analyses are 
shown with the number of exposed cases, original Or, adjusted Or and adjusted P-value
Morbidity category # Cases Original 
OR
EB-Adjusted 
OR
EB-Adjusted 
P-value
retinal detachments and breaks 23 0.59 0.93 0.70
Other diseases of arteries, arterioles and capillaries 97 0.84 0.93 0.67
Malignant neoplasm of cervix uteri 25 0.65 0.95 0.79
Pregnancies with abortive outcome 119 0.94 1.02 0.92
Paralytic ileus and intestinal obstruction without hernia 61 0.92 1.03 0.87
Bronchitis, emphysema and other chronic obstructive pulmonary diseases 238 1.00 1.03 0.82
Delivery without mention of complication 72 0.92 1.04 0.84
Osteoporosis (not including osteoporotic fracture) 108 0.99 1.05 0.78
Crohn’s disease and ulcerative colitis 36 0.88 1.05 0.79
Other malignant neoplasms of female genital organs 25 0.82 1.05 0.79
Abbreviations: PD, Parkinson’s disease; CI, confidence interval; OR, odds ratio; EB, empirical Bayes adjustment.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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as expected given the design, it could result in a substantial 
bias towards the null, explaining the differing results between 
the two definitions.
However, an alternative explanation could be due to 
increased fractures in PD cases due to early PD symptoms of 
postural instability. Postural instability is a classic symptom 
of PD and can lead to falls in PD cases; one study found a 38% 
risk of falling in PD cases.38 However, postural   instability is 
usually characteristic of later stages of PD, with the time until 
first fall an average of 9 years after the onset of the earliest 
symptoms, which are typically tremor or bradykinisia.39,40 
Therefore, it is unlikely that a large number of PD cases 
would have a PD-related fall five or more years before 
first appearance of a PD code. Nevertheless, the observed 
  association is small (OR = 1.18) and possible bias should be 
considered, especially as it may point to a longer preclinical, 
symptomatic phase of PD than often considered.
Empirical Bayes adjustment was used to identify novel 
associations warranting further investigation from   analyses of 
147 selected morbidity categories identified from the national 
registry of patients. Using a cutoff of an EB adjusted P-value 
of 0.05 identified 23 morbidity categories of   interest. In 
comparison, using the same P-value cutoff on the   unadjusted 
results would identify 61 categories for follow-up and using a 
Bonferroni P-value correction for 147 contrasts (P = 0.00034) 
would have resulted in the identification of 24 categories of 
interest (Appendix Table S2). The EB method showed a 
similar reduction in potential false-positive   findings as the 
conventional method, while likely improving the accuracy 
of the process by using the observed variance of the data to 
provide more precise estimates of association.
Many of the strongest associations identified after the EB 
analysis are psychological or neurological disorders (Table 3). 
Some of these associations, particularly to certain neurological 
diseases, may be due to long-term misdiagnoses before iden-
tifying the case as PD. The strong associations seen between 
PD and neurotic disorders, depression, and other mental and 
behavioral disorders more than 5 years before PD diagnosis 
may suggest that psychological   symptoms; which are known 
to be associated with both PD and dopamine levels, may be 
noticed in PD patients long before any traditional clinical signs 
of the disease manifest. Alternatively, this association could 
also be consistent with a common mechanism causing a sus-
ceptibility to loss of neurotransmitters. Examination of mental 
disorders before PD have shown consistent   associations 
with increased risk of PD in both case-control and cohort 
studies.41 A study examining both depression and anxiety 
disorders before PD found that the increased risk of PD seen 
after depression was attenuated when restricting depression 
diagnosis to more than 5 years in the past. Anxiety disorders 
however, continued to predict increased PD risk even when 
restricting to a lag of over 20 years between the diagnoses.42 
This pattern suggests depressive disorders may be more likely 
to represent early signs of PD, while anxiety disorders may be 
more likely to be associated with a casual mechanism.
Several of the other most strongly associated preceding 
conditions could be grouped together with other related 
c  onditions. Alcohol abuse, as well as liver disease and 
  pancreatitis (diseases often associated with alcohol abuse), all 
show a strong increased risk of subsequent PD.   Cirrhosis of the 
liver, which is often caused by alcohol abuse, has been associ-
ated with symptoms of Parkinsonism, and may be   associated 
with the accumulation of excess levels of   manganese which 
is related to the liver disease.43 These symptoms are distinct 
from idiopathic PD, although they may cause misclassification 
of PD cases that would bias the results for these associations, 
particularly in the liver disease category.
Alcohol use and abuse has been reported in some studies 
as protective of PD.44–46 Nevertheless, the finding of alcohol 
abuse related diseases positively associated with PD in this 
sample of Danish women is consistent with a prospective 
cohort study conducted in the United Kingdom, which found 
no overall association between alcoholism and PD, although 
the study did find an OR of 2.7 (95% CI 1.1–6.8) when only 
women were studied, albeit in a small number of cases.47 Taken 
together, these findings are suggestive that the effect of alcohol 
on PD risk may be sex-specific.   Interestingly, several studies 
have found an association between   alcohol   consumption and 
elevated circulating   estrogen levels in   premenopausal women 
and postmenopausal women using hormone replacement 
therapy (HRT) and not using HRT.48–51
Also of interest is the finding that several different inflam-
matory diseases (eg, rheumatism, cystitis, acute pancreatitis 
among others) associated with later risk of PD. Inflammation 
has been a topic of considerable study in the pathogenesis 
of PD, as inflammatory markers have been observed in the 
brains of PD patients.52 While the me  chanism is uncertain, 
and continued investigation is examining whether this 
inflammation is a cause or a   by-product of PD related neuro-
  degeneration, these   associations to inflammation related 
(albeit very clinically diverse)   diseases could be suggestive of 
a common   inflammation related mechanism. Finally, we also 
note several diseases related to the   gastrointestinal system 
and malnutrition associated with increased PD risk, which 
may be suggestive of a   malabsorption related mechanism 
for PD risk.Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
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The distribution of effects seen across the 147 morbidity 
categories were substantially skewed towards associations 
with increased risk (Figure 1). Very few associations showed 
a protective effect. Nevertheless, the most protective or least 
causal associations (identified in Table 4) are not unexpected 
findings. The known protective effect of smoking on PD is a 
likely reason for the nearly negative association between bron-
chitis, emphysema, and other chronic obstructive   pulmonary 
diseases and PD. Several of the least causally associated 
categories are estrogen related, including:   delivery without 
complications; pregnancies that had an abortive outcome; and 
malignant neoplasm of the cervix uteri and other female geni-
tal organs, consistent with the original hypothesis of the study, 
that conditions associated with estrogen may be associated 
with decreased risk of PD. The lack of protective associations 
observed in this study may be due to a form of Berkson’s bias 
in this sample. Berkson’s selection bias is based on the idea 
that people with two or more medical conditions are more 
likely to be hospitalized than people with only one medical 
condition. Higher rates of disease diagnosis may occur in 
people who seek out medical attention more frequently.
Strengths and limitations
This study is based on national registry data, and thus includes 
all female PD cases in Denmark, diagnosed between 1982 and 
2007, with well-matched controls. All exposure data are also 
derived from the registry and are not subject to recall bias. 
  Nevertheless, the results of these studies are limited in the 
ability to control for confounding, in particular by treatments 
associated with the preceding disease as well as important 
risk modifiers of PD and other diseases such as smoking. 
In addition, the use of hospital morbidity categories may 
provide less than ideal definitions for exposure categories. 
In some cases, rarer or less well understood diseases with 
very different causes and etiologies may be combined into 
one morbidity category. The study is further complicated by 
the uncertain latent and induction period for PD, although 
the insight into potential early preclinical signs of PD may 
be of equal importance to understanding the disease process 
as the understanding of causal mechanisms. It is not pos-
sible to distinguish whether observed associations arise from 
a causal effect of the   preceding disease or from common 
causal mechanisms underlying the etiology of both PD and 
the paired diseases.
Conclusion
In conclusion, the findings of a positive association between 
osteoporosis and PD and the relatively negative association 
seen to estrogen related morbidity categories in the 
EB analysis provides further evidence of estrogen related 
  neuro-protection against PD. The finding of no association 
between endometriosis and PD, however, does not   support 
this   protective relationship. The lack of   association between 
PD and endometriosis may indicate different estrogenic 
effects on the disease process; for example, a neuro-  protective 
mechanism based on long-term estrogen exposure and less 
dependent on high levels of estrogen at a given time, which 
may be more influential in endometriosis. In addition, several 
novel associations to PD were identified using EB analysis, 
which may lead to future insight into the disease process.
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Supplementary materials
Table S1 List of 202 morbidity categories and associated iCD-8 
and iCD-10 codes
Category ICD-codes
Cholera iCD-10: A00.0–A00.9
iCD-8: 0.0–0.9
Typhoid and paratyphoid fevers iCD-10: A01.0–A01.9
iCD-8: 1.0–1.9
iCD-8: 2.0–3.9
Other intestinal infectious diseases iCD-10: A02.0–A02.9
iCD-10: A04.0–A05.9
iCD-10: A07.0–A08.9
iCD-8: 5.0–5.9
iCD-8: 7.0–7.9
shigellosis/Bacillary dysentery iCD-10: A03.0–A03.9
iCD-8: 4.0–4.9
Amoebiasis iCD-10: A06.0–A06.9
iCD-8: 6.0–6.9
Diarrhea and gastro-enteritis of presumed 
infectious origin
iCD-10: A09.0–A09.9
iCD-8: 8.0–9.9
respiratory tuberculosis iCD-10: A15.0–A16.9
iCD-8: 10.0–12.3
iCD-8: 12.0–12.9
Other tuberculosis iCD-10: A17.0–A19.9
iCD-10: B90.0–B90.9
iCD-8: 13.0–19.9
Plague iCD-10: A20.0–A20.9
iCD-8: 20.0–20.9
Other bacterial diseases iCD-10: A21.0–A22.9
iCD-10: A24.0–A28.9
iCD-10: A31.0–A32.9
iCD-10: A38.0–A38.9
iCD-10: A42.0–A49.9
iCD-10: B96.0–B96.9
iCD-8: 21.0–22.9
iCD-8: 24.0–27.9
iCD-8: 31.0–31.9
iCD-8: 34.0–34.1
iCD-8: 35.0–35.9
iCD-8: 39.0–39.9
Brucellosis iCD-10: A23.0–A23.9
iCD-8: 23.0–23.9
Leprosy iCD-10: A30.0–A30.9
iCD-10: B92.0–B92.9
iCD-8: 30.0–30.9
Tetanus iCD-10: A33.0–A33.9
iCD-10: A34.0–A35.9
iCD-8: 37.0–37.9
Diphtheria iCD-10: A36.0–A36.9
iCD-8: 32.0–32.9
Whooping cough iCD-10: A37.0–A37.9
iCD-8: 33.0–33.9
Meningococcal infection iCD-10: A39.0–A39.9
iCD-8: 36.0–36.9
septicemia iCD-10: A40.0–A41.9
iCD-8: 38.0–38.9
Early syphilis iCD-10: A51.0–A51.9
iCD-8: 91.0–91.9
(Continued)
Table S1 (Continued)
Other syphilis iCD-10: A50.0–A50.9
iCD-10: A52.0–A53.9
iCD-8: 90.0–90.9
iCD-8: 92.0–97.9
gonococcal infection iCD-10: A54.0–A54.9
iCD-8: 98.0–98.9
Other infectious and parasitic diseases iCD-10: A55.0–A67.9
iCD-10: A69.0–A70.9
iCD-10: A74.0–A74.9
iCD-10: A77.0–A79.9
iCD-10: B35.0–B49.9
iCD-10: B58.0–B64.9
iCD-10: B85.0–B89.9
iCD-10: B94.0–B94.9
iCD-10: B99.0–B99.9
iCD-8: 130.0–136.9
iCD-8: 89.0–89.9
iCD-8: 99.0–117.9
relapsing fevers iCD-10: A68.0–A68.9
iCD-8: 88.0–88.9
Other viral diseases iCD-10: A71.0–A71.9
iCD-10: A81.0–A81.9
iCD-10: A87.0–A89.9
iCD-10: B00.0–B04.9
iCD-10: B07.0–B09.9
iCD-10: B20.0–B25.9
iCD-10: B27.0–B34.9
iCD-10: B97.0–B97.9
iCD-8: 45.0–46.9
iCD-8: 50.0–54.9
iCD-8: 57.0–57.9
iCD-8: 61.0–61.9
iCD-8: 66.0–66.9
iCD-8: 68.0–68.9
iCD-8: 73.0–79.9
Typhus and other rickettsioses iCD-10: A75.0–A75.9
iCD-8: 80.0–83.9
Acute poliomyelitis iCD-10: A80.0–A80.9
iCD-10: B91.0–B91.9
iCD-8: 40.0–44.9
rabies iCD-10: A82.0–A82.9
iCD-8: 71.0–71.9
Viral encephalitis iCD-10: A83.0–A86.9
iCD-8: 62.0–65.9
Other arthropod-borne viral fevers  
and viral hemorrhagic fevers
iCD-10: A90.0–A94.9
iCD-10: A96.0–A99.9
iCD-8: 67.0–67.9
Yellow fever iCD-10: A95.0–A95.9
iCD-8: 60.0–60.9
Measles iCD-10: B05.0–B05.9
iCD-8: 55.0–55.9
rubella iCD-10: B06.0–B06.9
iCD-8: 56.0–56.9
hepatitis iCD-10: B15.0–B15.9
iCD-10: B16.0–B16.9
iCD-10: B17.0–B19.9
iCD-8: 70.0–70.9
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Table S1 (Continued)
Category ICD-codes
Mumps iCD-10: B26.0–B26.9
iCD-8: 72.0–72.9
Malaria iCD-10: B50.0–B54.9
iCD-8: 84.0–84.9
Leishmaniasis iCD-10: B55.0–B55.9
iCD-8: 85.0–85.9
Trypanosomiasis iCD-10: B56.0–B57.9
iCD-8: 86.0–87.9
schistosomiasis iCD-10: B65.0–B65.9
iCD-8: 120.0–120.9
Other helminthiases iCD-10: B66.0–B66.9
iCD-10: B68.0–B75.9
iCD-10: B77.0–B83.9
iCD-8: 121.0–121.9
iCD-8: 123.0–125.9
iCD-8: 127.0–129.9
Echinococcosis/hydatidosis iCD-10: B67.0–B67.9
iCD-8: 122.0–122.9
hookworm diseases/Ankylostomiasis iCD-10: B76.0–B76.9
iCD-8: 126.0–126.9
Malignant neoplasm of lip, oral cavity  
and pharynx
iCD-10: C00.0–C14.9
iCD-8: 140.0–149.9
Malignant neoplasm of other digestive 
organs and peritoneum
iCD-10: C15.0–C15.9
iCD-10: C17.0–C17.9
iCD-10: C22.0–C26.9
iCD-8: 150.0–150.9
iCD-8: 155.0–159.9
Malignant neoplasm of stomach iCD-10: C16.0–C16.9
iCD-8: 151.0–151.9
Malignant neoplasm of colon iCD-10: C18.0–C18.9
iCD-8: 152.0–153.9
Malignant neoplasm of rectosigmoid 
junction, rectum, anus and anal canal
iCD-10: C19.0–C21.9
iCD-8: 154.0–154.9
Other malignant neoplasms of respiratory 
and intrathoracic organs
iCD-10: C30.0–C31.9
iCD-10: C37.0–C39.9
Malignant neoplasm of other and unspecified 
respiratory organs
iCD-8: 160.0–160.9
iCD-8: 163.0–163.9
Malignant neoplasm of larynx iCD-10: C32.0–C32.9
iCD-8: 161.0–161.9
Malignant neoplasm of trachea, bronchus 
and lung
iCD-10: C33.0–C34.9
iCD-8: 162.0–162.9
Malignant neoplasm of bone and articular 
cartilage
iCD-10: C40.0–C41.9
iCD-8: 170.0–170.9
Malignant neoplasm of skin iCD-10: C43.0–C43.9
iCD-10: C44.0–C44.9
iCD-8: 172.0–173.9
Malignant neoplasm of other specified sites iCD-10: C45.0–C49.9
iCD-10: C69.0–C70.9
iCD-10: C72.0–C72.9
iCD-8: 171.0–171.9
iCD-8: 190.0–190.9
iCD-8: 192.0–195.9
Malignant neoplasm of breast iCD-10: C50.0–C50.9
iCD-8: 174.0–174.9
Other malignant neoplasms of female genital 
organs
iCD-10: C51.0–C52.9
iCD-10: C56.0–C58.9
iCD-8: 181.0–181.9
iCD-8: 183.0–183.1
iCD-8: 183.0–184.9
(Continued)
Table S1 (Continued)
Malignant neoplasm of cervix uteri iCD-10: C53.0–C53.9
iCD-8: 180.0–180.9
Malignant neoplasm of other and unspecified 
parts of uterus
iCD-10: C54.0–C55.9
iCD-8: 182.0–182.9
Other malignant neoplasms of male genital 
organs
iCD-10: C60.0–C60.9
iCD-10: C62.0–C63.9
iCD-8: 186.0–186.9
Malignant neoplasm of prostate iCD-10: C61.0–C61.9
iCD-8: 185.0–185.9
Other malignant neoplasms of urinary tract iCD-10: C64.0–C66.9
iCD-10: C68.0–C68.9
Malignant neoplasm of other genitourinary 
organs
iCD-8: 187.0–187.9
iCD-8: 189.0–189.9
Malignant neoplasm of bladder iCD-10: C67.0–C67.9
iCD-8: 188.0–188.9
Malignant neoplasm of brain iCD-10: C71.0–C71.9
iCD-8: 191.0–191.9
Malignant neoplasm of other, ill-defined, 
secondary, unspecified and multiple sites
iCD-10: C73.0–C80.9
iCD-10: C97.0–C97.9
iCD-8: 197.0–199.9
hodgkin’s disease iCD-10: C81.0–C81.9
iCD-8: 201.0–201.9
Other malignant neoplasms of lymphoid, 
hematopoietic and related tissue
iCD-10: C82.0–C85.9
iCD-10: C88.0–C90.9
iCD-10: C96.0–C96.9
iCD-8: 196.0–196.9
iCD-8: 200.0–200.9
iCD-8: 202.0–203.9
iCD-8: 208.0–209.9
Leukemia iCD-10: C91.0–C95.9
iCD-8: 204.0–207.9
Other in situ and benign neoplasms and 
neoplasms of uncertain and unknown 
behavior
iCD-10: D00.0–D05.9
iCD-10: D07.0–D21.9
iCD-10: D24.0–D24.9
iCD-10: D26.0–D26.9
iCD-10: D28.0–D29.9
iCD-10: D31.0–D32.9
iCD-10: D34.0–D48.9
iCD-8: 210.0–215.9
iCD-8: 217.0–217.9
iCD-8: 219.0–219.9
iCD-8: 221.0–222.9
iCD-8: 224.0–224.9
iCD-8: 226.0–228.9
iCD-8: 230.0–239.9
Carcinoma in situ of cervix uteri iCD-10: D06.0–D06.9
iCD-8: 234.0–234.0
Benign neoplasm of skin iCD-10: D22.0–D23.9
iCD-8: 216.0–216.9
Leiomyoma of uterus iCD-10: D25.0–D25.9
iCD-8: 218.0–218.9
Benign neoplasm of ovary iCD-10: D27.0–D27.9
iCD-8: 220.0–220.9
Benign neoplasm of kidney and other urinary 
organs
iCD-10: D30.0–D30.9
iCD-8: 223.0–223.9
Benign neoplasm of brain and other parts of 
central nervous system
iCD-10: D33.0–D33.9
iCD-8: 225.0–225.9
Iron deficiency anemia iCD-10: D50.0–D50.9
iCD-8: 280.0–280.9
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Category ICD-codes
Other anemias iCD-10: D51.0–D64.9
iCD-8: 281.0–285.9
hemorrhagic conditions and other diseases 
of blood and blood-forming organs
iCD-10: D65.0–D77.9
iCD-8: 286.0–289.9
Other endocrine, nutritional and metabolic 
disorders
iCD-10: D80.0–D89.9
iCD-10: E15.0–E35.9
iCD-10: E58.0–E63.9
iCD-10: E65.0–E65.9
iCD-10: E66.0–E66.9
iCD-10: E67.0–E85.9
iCD-10: E87.0–E90.9
iCD-8: 251.0–258.9
iCD-8: 270.0–279.9
Other disorders of thyroid iCD-10: E03.0–E04.9
iCD-10: E06.0–E07.9
iCD-8: 240.0–241.9
iCD-8: 243.0–246.9
Iodine-deficiency-related thyroid disorders iCD-10: E00.0–E02.9
iCD-10: E05.0–E05.9
iCD-8: 242.0–242.9
Diabetes mellitus iCD-10: E10.0–E14.9
iCD-8: 249.0–250.9
Avitaminosis and other nutritional deficiency iCD-10: E40.0–E47.9
iCD-10: E50.0–E50.9
iCD-10: E51.0–E56.9
iCD-10: E64.0–E64.9
iCD-8: 260.0–269.9
Dementia iCD-10: F00.0–F03.9
iCD-10: g31.0–g31.0
iCD-8: 290.0–290.0
iCD-8: 290.0–290.9
Other mental and behavioral disorders iCD-10: F04.0–F09.9
iCD-10: F50.0–F69.9
iCD-10: F80.0–F99.9
iCD-8: 292.0–294.9
iCD-8: 297.0–299.9
iCD-8: 305.0–309.9
Alcohol-, drug-abuse-related disease iCD-10: F10.0–F19.9
iCD-8: 291.0–291.9
iCD-8: 303.0–304.9
schizophrenia, schizotypal and delusional 
disorders
iCD-10: F20.0–F29.9
iCD-8: 295.0–295.9
Mood [affective] disorders iCD-10: F30.0–F31.9
iCD-10: F34.0–F39.9
iCD-8: 296.0–296.1
iCD-8: 296.0–296.9
Depression iCD-10: F32.0–F33.9
iCD-8: 296.0–296.0
iCD-8: 296.0–296.2
neurotic, stress-related and somatoform 
disorders
iCD-10: F40.0–F48.9
iCD-8: 300.0–302.9
Mental retardation iCD-10: F70.0–F79.9
iCD-8: 310.0–315.9
Inflammatory diseases of the central nervous 
system
iCD-10: g00.0–g09.9
iCD-8: 320.0–320.9
iCD-8: 321.0–324.9
(Continued)
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Other diseases of the nervous system iCD-10: g10.0–g13.9
iCD-10: g21.0–g26.9
iCD-10: g31.1–g32.9
iCD-10: g36.0–g37.9
iCD-10: g44.0–g44.9
iCD-10: g46.0–g47.9
iCD-10: g50.0–g73.9
iCD-10: g80.0–g83.9
iCD-10: g90.0–g99.9
iCD-8: 330.0–333.9
iCD-8: 343.0–344.9
iCD-8: 347.0–358.9
Parkinson’s disease iCD-10: g20.0–g20.9
iCD-8: 342.0–342.9
Alzheimer’s disease iCD-10: g30.0–g30.9
iCD-8: 290.0–290.1
Multiple sclerosis and other demyelinating 
disease
iCD-10: g35.0–g35.9
iCD-8: 340.0–341.9
Epilepsy iCD-10: g40.0–g41.9
iCD-8: 345.0–345.9
Migraine iCD-10: g43.0–g43.9
iCD-8: 346.0–346.9
Transient cerebral ischemic attacks and 
related syndromes
iCD-10: g45.0–g45.9
iCD-8: 435.0–435.9
Other inflammatory diseases of eye iCD-10: h00.0–h01.9
iCD-10: h10.0–h13.9
iCD-10: h15.0–h19.9
iCD-8: 360.0–369.9
Other diseases of the eye and adnexa iCD-10: h02.0–h06.9
iCD-10: h20.0–h22.9
iCD-10: h30.0–h32.9
iCD-10: h34.0–h36.9
iCD-10: h43.0–h48.9
iCD-10: h51.0–h59.9
iCD-8: 370.0–372.9
iCD-8: 377.0–379.9
Cataract and other disorders of lens iCD-10: h25.0–h28.9
iCD-8: 374.0–374.9
retinal detachments and breaks iCD-10: h33.0–h33.9
iCD-8: 376.0–376.9
glaucoma iCD-10: h40.0–h42.9
iCD-8: 375.0–375.9
strabismus iCD-10: h49.0–h50.9
iCD-8: 373.0–373.9
Other diseases of the ear and mastoid 
process
iCD-10: h60.0–h62.9
iCD-10: h65.0–h75.9
iCD-10: h80.0–h83.9
iCD-10: h90.0–h95.9
iCD-8: 380.0–380.9
iCD-8: 381.0–381.9
iCD-8: 382.0–383.9
iCD-8: 384.0–389.9
Acute rheumatic fever iCD-10: i00.0–i02.9
iCD-8: 390.0–392.9
Chronic rheumatic heart disease iCD-10: i05.0–i09.9
iCD-8: 393.0–398.9
Essential (primary) hypertension iCD-10: i10.0–i15.9
iCD-8: 400.0–404.9
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Category ICD-codes
Angina pectoris iCD-10: i20.0–i20.9
iCD-8: 413.0–413.9
Acute myocardial infarction iCD-10: i21.0–i22.9
iCD-8: 410.0–410.9
Other ischemic heart diseases iCD-10: i23.0–i25.9
iCD-8: 411.0–412.9
Other ischemic heart disease iCD-8: 414.0–414.9
Pulmonary embolism iCD-10: i26.0–i26.9
iCD-8: 450.0–450.9
Other heart diseases iCD-10: i27.0–i43.9
iCD-10: i51.0–i52.9
iCD-8: 420.0–426.9
iCD-8: 428.0–429.9
Conduction disorders and cardiac 
arrhythmias
iCD-10: i44.0–i49.9
iCD-8: 427.0–427.9
Congestive heart failure iCD-10: i50.0–i50.9
iCD-8: 427.0–427.0
intracranial hemorrhage iCD-10: i60.0–i62.9
iCD-8: 431.0–431.9
Cerebral infarction iCD-10: i63.0–i63.9
iCD-8: 432.0–434.9
Other cerebrovascular diseases iCD-10: i64.0–i64.9
iCD-10: i65.0–i69.9
iCD-8: 430.0–430.9
iCD-8: 436.0–436.9
iCD-8: 437.0–438.9
Atherosclerosis iCD-10: i70.0–i70.9
iCD-8: 440.0–440.9
Other diseases of arteries, arterioles and 
capillaries
iCD-10: i71.0–i72.9
iCD-10: i74.0–i74.9
iCD-10: i77.0–i79.9
iCD-8: 441.0–442.9
iCD-8: 444.0–448.9
Other peripheral vascular diseases iCD-10: i73.0–i73.9
iCD-8: 443.0–443.9
Phlebitis, thrombophlebitis, venous 
embolism and thrombosis
iCD-10: i80.0–i82.9
iCD-8: 451.0–453.9
Varicose veins of lower extremities iCD-10: i83.0–i83.9
iCD-8: 454.0–454.9
hemorrhoids iCD-10: i84.0–i84.9
iCD-8: 455.0–455.9
Other diseases of the circulatory system iCD-10: i85.0–i99.9
iCD-8: 456.0–458.9
Other acute upper respiratory infections iCD-10: J00.0–J01.9
iCD-10: J04.0–J04.9
iCD-10: J05.0–J06.9
iCD-8: 460.0–461.9
iCD-8: 464.0–465.9
Acute pharyngitis and acute tonsillitis iCD-10: J02.0–J03.9
iCD-8: 34.0–34.0
iCD-8: 462.0–463.9
Influenza iCD-10: J10.0–J11.9
iCD-8: 470.0–474.9
Pneumonia iCD-10: J12.0–J18.9
iCD-8: 480.0–480.9
iCD-8: 481.0–481.9
iCD-8: 482.0–483.9
iCD-8: 484.0–486.9
Acute bronchitis and acute bronchiolitis iCD-10: J20.0–J21.9
iCD-8: 466.0–466.9
(Continued)
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Other diseases of the respiratory system iCD-10: J22.0–J22.9
iCD-10: J66.0–J99.9
iCD-8: 510.0–514.9
iCD-8: 517.0–517.9
iCD-8: 519.0–519.9
Other diseases of upper respiratory tract iCD-10: J30.0–J31.9
iCD-10: J33.0–J34.9
iCD-10: J36.0–J39.9
iCD-8: 501.0–502.9
iCD-8: 504.0–504.9
iCD-8: 505.0–508.9
Chronic sinusitis iCD-10: J32.0–J32.9
iCD-8: 503.0–503.9
Chronic disease of tonsils and adenoids iCD-10: J35.0–J35.9
iCD-8: 500.0–500.9
Bronchitis, emphysema and other chronic 
obstructive pulmonary diseases
iCD-10: J40.0–J44.9
iCD-10: J45.0–J46.9
iCD-8: 490.0–493.9
Bronchiectasis iCD-10: J47.0–J47.9
iCD-8: 518.0–518.9
Pneumoconioses and related diseases iCD-10: J60.0–J65.9
iCD-8: 515.0–516.9
Other diseases of the teeth, oral cavity, 
salivary glands and jaws
iCD-10: K00.0–K14.9
iCD-8: 520.0–529.9
Other diseases of esophagus, stomach and 
duodenum
iCD-10: K20.0–K23.9
iCD-10: K28.0–K28.9
iCD-10: K30.0–K31.9
iCD-8: 530.0–530.9
iCD-8: 536.0–537.9
gastric and duodenal ulcer iCD-10: K25.0–K27.9
iCD-8: 531.0–534.9
gastritis and duodenitis iCD-10: K29.0–K29.9
iCD-8: 535.0–535.9
Diseases of appendix iCD-10: K35.0–K38.9
iCD-8: 540.0–543.9
hernia iCD-10: K40.0–K46.9
iCD-8: 550.0–553.9
Crohn’s disease and ulcerative colitis iCD-10: K50.0–K51.9
iCD-8: 563.0–563.9
Other diseases of the digestive system iCD-10: K52.0–K55.9
iCD-10: K57.0–K67.9
iCD-10: K82.0–K83.9
iCD-10: K87.0–K93.9
iCD-8: 561.0–562.9
iCD-8: 564.0–569.9
Paralytic ileus and intestinal obstruction 
without hernia
iCD-10: K56.0–K56.9
iCD-8: 560.0–560.9
Other diseases of liver and gallbladder iCD-10: K70.0–K77.9
iCD-8: 570.0–573.9
iCD-8: 576.0–576.9
Cholelithiasis and cholecystitis iCD-10: K80.0–K81.9
iCD-8: 574.0–575.9
Acute pancreatitis and other diseases of the 
pancreas
iCD-10: K85.0–K86.9
iCD-8: 577.0–577.9
infections of the skin and subcutaneous 
tissue
iCD-10: L00.0–L08.9
iCD-8: 680.0–686.9
Other diseases of the skin and subcutaneous 
tissue
iCD-10: L10.0–L99.9
iCD-8: 690.0–698.9
iCD-8: 700.0–709.9
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Category ICD-codes
Other disorders of joints iCD-10: M00.0–M03.9
iCD-10: M22.0–M25.9
iCD-8: 724.0–724.9
iCD-8: 726.0–727.9
iCD-8: 729.0–729.9
iCD-8: 737.0–737.9
Rheumatoid arthritis and other inflammatory 
polyarthropathies
iCD-10: M05.0–M14.9
iCD-8: 712.0–712.9
iCD-8: 716.0–716.9
Osteoarthritis and allied conditions iCD-10: M15.0–M19.9
iCD-10: M47.0–M47.9
iCD-10: M48.3–M48.3
iCD-8: 710.0–711.9
iCD-8: 713.0–715.9
Acquired deformities of limbs iCD-10: M20.0–M21.9
iCD-8: 736.0–736.9
Other diseases of the musculoskeletal 
system and connective tissue
iCD-10: M30.0–M36.9
iCD-10: M87.0–M90.9
iCD-10: M94.0–M99.9
iCD-8: 730.0–730.9
iCD-8: 733.0–734.9
iCD-8: 738.0–738.9
Other dorsopathies iCD-10: M40.0–M41.9
iCD-10: M43.0–M43.5
iCD-10: M43.7-M46.9
iCD-10: M48.0–M48.2
iCD-10: M48.4–M49.9
iCD-10: M53.0–M53.9
iCD-8: 735.0–735.9
Osteochondrosis iCD-10: M42.0–M42.9
iCD-10: M91.0–M93.9
iCD-8: 722.0–722.9
rheumatism iCD-10: M43.6–M43.6
iCD-10: M79.0–M79.1
iCD-8: 717.0–718.9
Cervical and other intervertebral disk 
disorders
iCD-10: M50.0–M51.9
iCD-10: M54.0–M54.9
iCD-8: 725.0–725.9
iCD-8: 728.0–728.9
Myositis iCD-10: M60.0–M60.9
iCD-8: 732.0–732.9
soft tissue disorders iCD-10: M61.0–M78.9
iCD-10: M79.2–M79.5
iCD-10: M79.7–M79.9
iCD-8: 731.0–731.9
Osteoporosis with and without fracture iCD-10: M80.0–M81.9
iCD-8: 723.0–723.0
Other diseases of bone iCD-10: M82.0–M85.9
iCD-8: 721.0–721.9
iCD-8: 723.0–723.9
Osteomyelitis and periostitis iCD-10: M86.0–M86.9
iCD-8: 720.0–720.9
nephritis and nephrosis iCD-10: n00.0–n08.9
iCD-8: 580.0–584.9
infections of kidney iCD-10: n10.0–n16.9
iCD-8: 590.0–590.9
Other diseases of the urinary system iCD-10: n17.0–n19.9
iCD-10: n25.0–n29.9
iCD-10: n31.0–n39.9
iCD-8: 591.0–591.9
(Continued)
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iCD-8: 593.0–593.9
iCD-8: 596.0–599.9
Urolithiasis/Calculus of urinary system iCD-10: n20.0–n23.9
iCD-8: 592.0–592.9
iCD-8: 594.0–594.9
Cystitis iCD-10: n30.0–n30.9
iCD-8: 595.0–595.9
hyperplasia of prostate iCD-10: n40.0–n40.9
iCD-8: 600.0–600.9
Other diseases of male genital organs iCD-10: n41.0–n42.9
iCD-10: n44.0–n46.9
iCD-10: n48.0–n51.9
iCD-8: 601.0–602.9
iCD-8: 604.0–604.9
iCD-8: 606.0–607.9
hydrocele and spermatocele iCD-10: n43.0–n43.9
iCD-8: 603.0–603.9
redundant prepuce, phimosis and 
paraphimosis
iCD-10: n47.0–n47.9
iCD-8: 605.0–605.9
Disorders of breast iCD-10: n60.0–n64.9
iCD-8: 610.0–611.9
salpingitis and oophoritis iCD-10: n70.0–n70.9
iCD-8: 612.0–614.9
Other inflammatory diseases of female 
pelvic organs
iCD-10: n71.0–n71.9
iCD-10: n73.0–n77.9
iCD-8: 622.0–622.9
Inflammatory disease of cervix uteri iCD-10: n72.0–n72.9
iCD-8: 620.0–620.9
Endometriosis iCD-10: n80.0–n80.9
iCD-8: 625.0–625.3
Female genital prolapse iCD-10: n81.0–n81.9
iCD-8: 623.0–623.9
Other disorders of genitourinary tract iCD-10: n82.0–n82.9
iCD-10: n84.0–n90.9
iCD-10: n93.0–n96.9
iCD-10: n98.0–n99.9
iCD-8: 621.0–621.9
iCD-8: 624.0–625.9
iCD-8: 627.0–627.9
iCD-8: 629.0–629.9
Other diseases of ovary, fallopian tube and 
parametrium
iCD-10: n83.0–n83.9
iCD-8: 615.0–616.9
Disorders of menstruation iCD-10: n91.0–n92.9
iCD-8: 626.0–626.9
Female infertility iCD-10: n97.0–n97.9
iCD-8: 628.0–628.9
Ectopic pregnancy iCD-10: O00.0–O00.9
iCD-8: 631.0–631.9
Pregnancies with abortive outcome iCD-10: O01.0–O08.9
iCD-8: 640.0–645.9
Other complications of pregnancy or 
delivery
iCD-10: O10.0–O16.9
iCD-10: O20.0–O48.9
iCD-10: O60.0–O75.9
iCD-10: O81.0–O99.9
iCD-8: 630.0–639.9
iCD-8: 651.0–666.9
iCD-8: 670.0–678.9
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Delivery without mention of complication iCD-10: O80.0–O80.9
iCD-8: 650.0–650.9
Conditions originating in the perinatal 
period
iCD-10: P00.0–P54.9
iCD-10: P56.0–P96.9
iCD-8: 760.0–773.9
iCD-8: 776.0–779.9
hemolytic disease of fetus and newborn iCD-10: P55.0–P55.9
iCD-8: 774.0–775.9
Spina bifida and congenital hydrocephalus iCD-10: Q05.0–Q05.9
iCD-8: 741.0–742.9
Congenital malformations of the circulatory 
system
iCD-10: Q20.0–Q28.9
iCD-8: 746.0–747.9
Cleft lip and cleft palate iCD-10: Q35.0–Q37.9
iCD-8: 749.0–749.9
Other congenital malformations of the 
digestive system
iCD-10: Q38.0–Q40.9
iCD-10: Q42.0–Q45.9
iCD-8: 750.0–750.0
iCD-8: 750.0–750.9
iCD-8: 751.0–751.9
Absence, atresia and stenosis of small 
intestine
iCD-10: Q41.0–Q41.9
iCD-8: 750.0–750.1
Other malformations of the genitourinary 
system
iCD-10: Q50.0–Q52.9
iCD-10: Q54.0–Q64.9
iCD-8: 752.2–753.9
(Continued)
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Undescended testicle iCD-10: Q53.0–Q53.9
iCD-8: 752.0–752.1
Congenital deformities of hip iCD-10: Q65.0–Q65.9
iCD-8: 755.0–755.6
Congenital deformities of feet iCD-10: Q66.0–Q66.9
iCD-8: 754.0–754.9
Other congenital malformations and 
deformations of the musculoskeletal system
iCD-10: Q67.0–Q79.9
iCD-8: 755.0–755.9
iCD-8: 755.0–756.9
iCD-8: 756.0–756.9
Other and unspecified congenital anomalies iCD-10: Q00.0–Q04.9
iCD-10: Q06.0–Q07.9
iCD-10: Q10.0–Q18.9
iCD-10: Q30.0–Q34.9
iCD-10: Q80.0–Q99.9
iCD-8: 740.0–740.9
iCD-8: 743.0–745.9
iCD-8: 748.0–748.9
iCD-8: 757.0–759.9
Abdominal and pelvic pain iCD-10: r10.0–r10.9
iCD-8: 785.0–785.5
senility iCD-10: r54.0–r54.9
iCD-8: 794.0–794.9Clinical Epidemiology 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
168
Latourelle et al
Table S2 All 147 morbidity categories with 5 or more cases of PD are shown with the number of exposed cases, original Or and 
P-value, and EB adjusted odds ratio and P-value
Category # Cases Original  
OR
Original  
P-value
Adjusted  
OR
Adjusted 
P-value
neurotic, stress-related and somatoform disorders 278 2.35 ,0.0001 2.16 1.5 3 1027
Other diseases of the nervous system 314 1.64 ,0.0001 1.59 0.001
Depression 77 2.02 ,0.0001 1.7 0.001
Alcohol-, drug-abuse-related disease 104 1.85 ,0.0001 1.65 0.002
rheumatism 327 1.56 ,0.0001 1.52 0.004
Other mental and behavioral disorders 99 1.72 ,0.0001 1.56 0.006
Mood [affective] disorders 34 2.37 ,0.0001 1.65 0.006
Cystitis 307 1.52 ,0.0001 1.48 0.006
Mental retardation 22 3.15 ,0.0001 1.68 0.007
Acute pancreatitis and other diseases of the pancreas 62 1.84 ,0.0001 1.57 0.008
Epilepsy 95 1.67 ,0.0001 1.52 0.009
Angina pectoris 326 1.48 ,0.0001 1.45 0.01
Other diseases of the circulatory system 51 1.8 0.0001 1.52 0.016
Iodine-deficiency-related thyroid disorders 210 1.45 ,0.0001 1.41 0.02
Diabetes mellitus 303 1.41 ,0.0001 1.39 0.023
respiratory tuberculosis 27 2.12 0.0004 1.53 0.024
Other ischemic heart diseases 396 1.37 ,0.0001 1.36 0.031
Other infectious and parasitic diseases 64 1.58 0.0007 1.44 0.032
Other endocrine, nutritional and metabolic disorders 302 1.38 ,0.0001 1.36 0.034
Other diseases of liver and gallbladder 95 1.48 0.0004 1.4 0.037
Migraine 75 1.52 0.0009 1.41 0.038
gastritis and duodenitis 171 1.39 ,0.0001 1.36 0.042
Disorders of menstruation 802 1.32 ,0.0001 1.32 0.045
Other diseases of esophagus stomach and duodenum 177 1.36 0.0001 1.34 0.053
Congenital malformations of the circulatory system 16 2.27 0.003 1.46 0.053
nephritis and nephrosis 19 2.06 0.0042 1.45 0.054
Inflammatory diseases of the central nervous system 22 1.93 0.0048 1.44 0.054
Congestive heart failure 155 1.36 0.0004 1.33 0.06
infections of the skin and subcutaneous tissue 109 1.39 0.0014 1.35 0.061
Dementia 53 1.5 0.006 1.38 0.062
strabismus 33 1.59 0.0134 1.39 0.074
Other diseases of the digestive system 556 1.29 ,0.0001 1.28 0.074
Diarrhea and gastro-enteritis of presumed infectious origin 106 1.35 0.0036 1.32 0.08
Influenza 45 1.47 0.0167 1.35 0.086
Avitaminosis and other nutritional deficiency 22 1.7 0.0217 1.38 0.088
Acute pharyngitis and acute tonsillitis 21 1.72 0.0221 1.38 0.089
Other tuberculosis 20 1.73 0.0237 1.38 0.092
Other disorders of genitourinary tract 229 1.28 0.0005 1.28 0.098
Other disorders of thyroid 259 1.28 0.0002 1.27 0.099
Other anemias 100 1.32 0.0086 1.3 0.102
Malignant neoplasm of other and unspecified parts of uterus 108 1.32 0.0073 1.3 0.103
Abdominal and pelvic pain 213 1.27 0.0011 1.27 0.113
Essential (primary) hypertension 458 1.25 ,0.0001 1.25 0.113
Other diseases of the urinary system 189 1.27 0.0019 1.27 0.115
Iron deficiency anemia 65 1.33 0.03 1.3 0.124
Benign neoplasm of brain and other parts of central nervous system 31 1.43 0.062 1.32 0.132
Conditions originating in the perinatal period 7 2.55 0.0303 1.36 0.133
Endometriosis 42 1.37 0.0551 1.3 0.134
Transient cerebral ischemic attacks and related syndromes 144 1.26 0.01 1.25 0.142
gastric and duodenal ulcer 278 1.23 0.0012 1.23 0.151
Malignant neoplasm of other, ill-defined, secondary, unspecified, multiple 
sites
25 1.42 0.0999 1.31 0.155
Malignant neoplasm of bladder 22 1.44 0.1074 1.31 0.158
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Table S2 (Continued)
Category # Cases Original  
OR
Original  
P-value
Adjusted  
OR
Adjusted 
P-value
hemorrhagic conditions and other diseases of blood and blood-forming 
organs
34 1.35 0.1043 1.29 0.166
hemorrhoids 155 1.23 0.0168 1.23 0.176
septicemia 31 1.34 0.125 1.28 0.176
Other congenital malformations of the digestive system 12 1.58 0.1397 1.31 0.177
Other inflammatory diseases of female pelvic organs 87 1.25 0.0519 1.24 0.178
Other viral diseases 89 1.24 0.0565 1.24 0.186
Other peripheral vascular diseases 26 1.35 0.1562 1.28 0.188
Other diseases of bone 26 1.34 0.1574 1.28 0.188
soft tissue disorders 219 1.21 0.0096 1.21 0.192
hernia 296 1.2 0.0032 1.21 0.194
Pulmonary embolism 50 1.26 0.1288 1.25 0.202
Leukemia 10 1.52 0.2144 1.29 0.207
Other diseases of the eye and adnexa 264 1.19 0.0083 1.2 0.216
Malignant neoplasm of stomach 11 1.45 0.2499 1.28 0.217
Acute rheumatic fever 8 1.56 0.2437 1.29 0.218
Cervical and other intervertebral disk disorders 377 1.18 0.0027 1.19 0.227
Acute bronchitis and acute bronchiolitis 51 1.23 0.1642 1.23 0.227
Acute poliomyelitis 8 1.5 0.2839 1.28 0.229
Female genital prolapse 582 1.18 0.0003 1.18 0.232
Other malignant neoplasms of lymphoid, hematopoietic  
and related tissue
38 1.23 0.2248 1.23 0.239
Osteomyelitis and periostitis 14 1.32 0.3293 1.26 0.244
Malignant neoplasm of colon 73 1.2 0.1426 1.21 0.245
schizophrenia, schizotypal and delusional disorders 9 1.4 0.348 1.26 0.246
Malignant neoplasm of other specified sites 17 1.28 0.3412 1.25 0.251
Other dorsopathies 63 1.2 0.1802 1.21 0.255
Chronic disease of tonsils and adenoids 14 1.29 0.3818 1.25 0.259
Conduction disorders and cardiac arrhythmias 326 1.17 0.0092 1.18 0.26
Other intestinal infectious diseases 8 1.33 0.4449 1.25 0.269
Other diseases of the ear and mastoid process 379 1.16 0.0085 1.17 0.271
Phlebitis, thrombophlebitis, venous embolism and thrombosis 133 1.17 0.0871 1.19 0.272
Other diseases of the musculoskeletal system and connective tissue 154 1.17 0.0752 1.18 0.28
Cataract and other disorders of lens 451 1.15 0.006 1.16 0.289
Pneumonia 264 1.16 0.029 1.17 0.293
Other bacterial diseases 56 1.17 0.274 1.2 0.297
Other inflammatory diseases of eye 62 1.16 0.2832 1.19 0.313
Other malformations of the genitourinary system 24 1.16 0.4998 1.21 0.32
Inflammatory disease of cervix uteri 21 1.16 0.5317 1.21 0.322
Benign neoplasm of kidney and other urinary organs 32 1.14 0.4716 1.19 0.331
Malignant neoplasm of other genitourinary organs 12 1.14 0.6703 1.21 0.332
Ectopic pregnancy 11 1.14 0.6928 1.21 0.332
Leiomyoma of uterus 226 1.14 0.0711 1.15 0.333
Female infertility 13 1.11 0.7316 1.2 0.35
hepatitis 5 1 0.9949 1.21 0.364
Malignant neoplasm of skin 68 1.12 0.3765 1.16 0.371
Disorders of breast 170 1.12 0.1573 1.14 0.375
Bronchiectasis 5 0.95 0.9209 1.2 0.379
Other diseases of ovary, fallopian tube and parametrium 79 1.11 0.3682 1.15 0.386
Urolithiasis/Calculus of urinary system 101 1.12 0.2983 1.15 0.387
Malignant neoplasm of trachea, bronchus and lung 13 1.04 0.8886 1.18 0.393
Typhoid and paratyphoid fevers 5 0.86 0.7477 1.19 0.412
Benign neoplasm of ovary 108 1.11 0.3277 1.14 0.413
Other in situ and benign neoplasms or of uncertain/unknown behavior 596 1.11 0.0191 1.12 0.42
Other diseases of upper respiratory tract 95 1.1 0.3793 1.14 0.42
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Table S2 (Continued)
Category # Cases Original  
OR
Original  
P-value
Adjusted  
OR
Adjusted 
P-value
Other congenital malformations/deformations  
of the musculoskeletal system
22 1.05 0.8351 1.16 0.422
glaucoma 111 1.09 0.3709 1.13 0.44
intracranial hemorrhage 19 1 0.9909 1.15 0.457
Other cerebrovascular diseases 219 1.09 0.2137 1.11 0.464
Diseases of appendix 119 1.08 0.416 1.12 0.475
Chronic sinusitis 18 0.97 0.8932 1.14 0.488
Acute myocardial infarction 235 1.09 0.2379 1.11 0.493
Multiple sclerosis and other demyelinating disease 13 0.91 0.737 1.14 0.5
Other diseases of the skin and subcutaneous tissue 183 1.08 0.3258 1.11 0.501
Carcinoma in situ of cervix uteri 53 1.05 0.7547 1.12 0.501
Cerebral infarction 102 1.07 0.5218 1.11 0.502
Malignant neoplasm of lip, oral cavity and pharynx 7 0.77 0.4979 1.15 0.503
Other complications of pregnancy or delivery 133 1.06 0.6019 1.11 0.506
Osteochondrosis 21 0.95 0.8228 1.13 0.533
Other diseases of the teeth, oral cavity, salivary glands and jaws 76 1.04 0.7218 1.11 0.544
Malignant neoplasm of breast 211 1.07 0.3679 1.09 0.548
salpingitis and oophoritis 20 0.93 0.7426 1.12 0.554
Other heart diseases 77 1.04 0.7586 1.1 0.562
Acquired deformities of limbs 31 0.97 0.8887 1.11 0.564
Osteoarthritis and allied conditions 692 1.07 0.0898 1.08 0.568
Cholelithiasis and cholecystitis 383 1.07 0.232 1.08 0.576
Other and unspecified congenital anomalies 26 0.95 0.7927 1.11 0.576
Chronic rheumatic heart disease 24 0.94 0.7585 1.11 0.577
Other diseases of the respiratory system 90 1.03 0.7592 1.09 0.588
Varicose veins of lower extremities 347 1.06 0.3149 1.08 0.605
Other acute upper respiratory infections 23 0.91 0.6469 1.1 0.617
infections of kidney 76 1.02 0.8962 1.09 0.62
Other diseases of arteries, arterioles and capillaries 97 0.84 0.0963 0.93 0.673
Benign neoplasm of skin 31 0.91 0.6085 1.08 0.688
retinal detachments and breaks 23 0.59 0.014 0.93 0.699
Rheumatoid arthritis and other inflammatory polyarthropathies 119 1.01 0.9178 1.06 0.704
Malignant neoplasm of rectosigmoid junction, rectum, anus, anal canal 29 0.89 0.5322 1.07 0.713
Atherosclerosis 89 0.99 0.9518 1.06 0.714
Other disorders of joints 128 1 0.9646 1.05 0.736
Osteoporosis with and without fracture 108 0.99 0.8846 1.05 0.776
Malignant neoplasm of cervix uteri 25 0.65 0.0346 0.95 0.79
Other malignant neoplasms of female genital organs 25 0.82 0.35 1.05 0.79
Crohn’s disease and ulcerative colitis 36 0.88 0.4703 1.05 0.792
Bronchitis, emphysema and other chronic  
obstructive pulmonary diseases
238 1 0.9632 1.03 0.824
Delivery without mention of complication 72 0.92 0.5339 1.04 0.839
Paralytic ileus and intestinal obstruction without hernia 61 0.92 0.5124 1.03 0.871
Pregnancies with abortive outcome 119 0.94 0.5711 1.02 0.922
Abbreviations: Or, odds ratio; PD, Parkinson’s disease; EB, empirical Bayes.